About Puma Biotechnology (NYSE:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NYSE:PBYI
- CUSIP: N/A
- Web: www.pumabiotechnology.com/
Capitalization:- Market Cap: $4.64 billion
- Outstanding Shares: 37,205,000
Average Prices:- 50 Day Moving Avg: $112.81
- 200 Day Moving Avg: $79.93
- 52 Week Range: $28.35 - $127.02
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -26.58
- P/E Growth: 0.03
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.24 per share
- Price / Book: 38.47
Profitability:- EBITDA: ($289,010,000.00)
- Return on Equity: -217.17%
- Return on Assets: -160.32%
Debt:- Current Ratio: 3.12%
- Quick Ratio: 3.12%
Misc:- Average Volume: 818,798 shs.
- Beta: 0.35
- Short Ratio: 6.75
Frequently Asked Questions for Puma Biotechnology (NYSE:PBYI)
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NYSE:PBYI) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by $0.78. View Puma Biotechnology's Earnings History.
When will Puma Biotechnology make its next earnings announcement?
Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?
9 analysts have issued 1-year price targets for Puma Biotechnology's stock. Their forecasts range from $88.00 to $156.00. On average, they anticipate Puma Biotechnology's share price to reach $124.89 in the next year. View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alkermes PLC (ALKS), Icon Plc (ICLR), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), United Therapeutics Corporation (UTHR), Galapagos NV (GLPG), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Ligand Pharmaceuticals Incorporated (LGND).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer
- Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer
- Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer
- Steven Lo, Chief Commercial Officer
- Jay M. Moyes, Independent Director
- Adrian M. Senderowicz M.D., Independent Director
- Troy E. Wilson Ph.D. J.D., Independent Director
- Frank E. Zavrl, Independent Director
Who owns Puma Biotechnology stock?
Puma Biotechnology's stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.04%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?
How do I buy Puma Biotechnology stock?
Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of Puma Biotechnology stock can currently be purchased for approximately $124.65.
MarketBeat Community Rating for Puma Biotechnology (NYSE PBYI)MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Puma Biotechnology (NYSE:PBYI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.89) |
| Consensus Price Target: | $124.89 (0.19% upside) |
Consensus Price Target History for Puma Biotechnology (NYSE:PBYI)
Analysts' Ratings History for Puma Biotechnology (NYSE:PBYI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/9/2017 | Bank of America Corporation | Reiterated Rating | Buy | $117.00 -> $135.00 | N/A |  |
| 10/5/2017 | Citigroup Inc. | Reiterated Rating | Buy | $114.00 -> $156.00 | N/A | |
| 10/4/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | $131.00 | High | |
| 10/2/2017 | Stifel Nicolaus | Boost Price Target | Buy | $110.00 -> $130.00 | Low | |
| 9/27/2017 | Credit Suisse Group | Reiterated Rating | Outperform | $136.00 | High | |
| 9/6/2017 | Barclays PLC | Initiated Coverage | Overweight | $103.00 | High | |
| 8/2/2017 | Leerink Swann | Reiterated Rating | Outperform | $125.00 | Low | |
| 7/22/2017 | Cowen and Company | Reiterated Rating | Outperform | $91.00 -> $120.00 | Medium | |
| 7/17/2017 | Royal Bank Of Canada | Set Price Target | Hold | $88.00 | Medium | |
| 1/5/2016 | Berenberg Bank | Upgrade | Hold -> Buy | | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Puma Biotechnology (NYSE:PBYI)Earnings History by Quarter for Puma Biotechnology (NYSE PBYI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($2.50) | | | | | N/A | |
| 8/9/2017 | Q2 2017 | ($1.32) | ($2.10) | | | View | N/A | |
| 5/10/2017 | Q1 2017 | ($2.06) | ($1.97) | | | View | N/A | |
| 3/1/2017 | Q4 | ($1.92) | ($2.04) | | | View | N/A | |
| 5/10/2016 | Q1 | ($1.99) | ($1.28) | | | View | N/A | |
| 2/29/2016 | Q4 | ($1.95) | ($1.23) | | | View | N/A | |
| 11/9/2015 | Q3 | ($1.84) | ($1.87) | | | View | N/A | |
| 8/10/2015 | Q2 | ($1.55) | ($1.13) | | | View | N/A | |
| 5/11/2015 | Q1 | ($1.25) | ($1.02) | | | View | N/A | |
| 3/2/2015 | | ($1.15) | ($1.59) | | | View | N/A | |
| 11/10/2014 | | ($1.27) | ($1.19) | | | View | N/A | |
| 8/11/2014 | Q214 | ($0.66) | ($1.05) | | | View | N/A | |
| 5/12/2014 | | ($0.48) | ($0.67) | | | View | N/A | |
| 3/3/2014 | Q413 | ($0.49) | ($0.46) | | | View | N/A | |
| 4/1/2013 | Q413 | ($0.70) | ($0.25) | | | View | N/A | |
| 11/14/2012 | Q312 | | ($1.29) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Puma Biotechnology (NYSE:PBYI)Current Year EPS Consensus Estimate: $-8.69 EPS
Next Year EPS Consensus Estimate: $-4.69 EPS
Dividend History for Puma Biotechnology (NYSE:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Puma Biotechnology (NYSE:PBYI)Insider Ownership Percentage: 22.70%
Institutional Ownership Percentage: 80.98%
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/29/2017 | Richard Paul Bryce | SVP | Sell | 15,000 | $120.00 | $1,800,000.00 | |
| 9/7/2017 | Richard Paul Bryce | SVP | Sell | 15,000 | $100.09 | $1,501,350.00 | |
| 7/20/2017 | Alan H Auerbach | Insider | Sell | 13,175 | $94.73 | $1,248,067.75 | |
| 7/20/2017 | Richard Paul Bryce | SVP | Sell | 1,998 | $94.48 | $188,771.04 | |
| 7/3/2017 | Richard Paul Bryce | SVP | Sell | 5,000 | $87.10 | $435,500.00 | |
| 6/12/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 247,260 | $80.32 | $19,859,923.20 | |
| 6/5/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 507,128 | $87.84 | $44,546,123.52 | |
| 5/26/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 1,235,700 | $75.38 | $93,147,066.00 | |
| 2/1/2017 | Robert Charnas | Insider | Sell | 3,008 | $31.83 | $95,744.64 | |
| 1/20/2017 | Alan H Auerbach | Insider | Sell | 10,202 | $33.24 | $339,114.48 | |
| 1/20/2017 | Richard Paul Bryce | SVP | Sell | 2,293 | $33.24 | $76,219.32 | |
| 7/6/2015 | Richard Paul Bryce | SVP | Sell | 3,000 | $110.03 | $330,090.00 | |
| 11/8/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 22,549 | $38.92 | $877,607.08 | |
| 11/5/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 280,700 | $39.60 | $11,115,720.00 | |
| 10/9/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 140,900 | $40.44 | $5,697,996.00 | |
| 12/18/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 29,560 | $19.00 | $561,640.00 | |
| 12/12/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 30,400 | $19.00 | $577,600.00 | |
| 12/11/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 140,040 | $18.98 | $2,657,959.20 | |
| 10/24/2012 | Thomas Malley | Director | Buy | 10,000 | $16.00 | $160,000.00 | |
| 10/18/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 610,000 | $16.00 | $9,760,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Puma Biotechnology (NYSE:PBYI)
Latest Headlines for Puma Biotechnology (NYSE:PBYI)
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $3.60 Million
www.americanbankingnews.com - October 17 at 6:52 AM |
| Head-To-Head Comparison: Puma Biotechnology (PBYI) versus Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - October 17 at 6:30 AM |
| Puma Biotechnology (PBYI) & Its Rivals Head-To-Head Review
www.americanbankingnews.com - October 14 at 12:36 PM |
| Puma Biotechnology Inc (PBYI) Given "Buy" Rating at Bank of America Corporation
www.americanbankingnews.com - October 9 at 8:20 PM |
 | Citigroup: Puma Biotech, Up 300% Since May, Is A Takeover Target - Benzinga
www.benzinga.com - October 5 at 8:26 PM |
| Puma Biotechnology's (PBYI) Buy Rating Reiterated at Citigroup Inc.
www.americanbankingnews.com - October 5 at 4:56 PM |
 | XBI, CLVS, SRPT, PBYI: Large Inflows Detected at ETF
www.nasdaq.com - October 5 at 3:18 PM |
| Puma Biotechnology Inc (PBYI) Earns Buy Rating from J P Morgan Chase & Co
www.americanbankingnews.com - October 4 at 11:44 PM |
| Puma Biotechnology Inc (PBYI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 4 at 12:54 PM |
| Puma Biotechnology Inc (PBYI) SVP Sells $1,800,000.00 in Stock
www.americanbankingnews.com - October 2 at 7:16 PM |
 | Puma Biotech price target raised by 20% to $130 at Stifel
www.marketwatch.com - October 2 at 10:48 AM |
| Stifel Nicolaus Increases Puma Biotechnology Inc (PBYI) Price Target to $130.00
www.americanbankingnews.com - October 2 at 7:53 AM |
| $3.00 Million in Sales Expected for Puma Biotechnology Inc (PBYI) This Quarter
www.americanbankingnews.com - September 28 at 4:50 AM |
| Puma Biotechnology Inc (PBYI) Earns "Outperform" Rating from Credit Suisse Group
www.americanbankingnews.com - September 27 at 9:58 PM |
 | Turnout high as Iraqi Kurds defy threats to hold independence vote
www.streetinsider.com - September 27 at 8:18 PM |
| -$2.71 EPS Expected for Puma Biotechnology Inc (PBYI) This Quarter
www.americanbankingnews.com - September 26 at 6:16 PM |
| Head to Head Comparison: Puma Biotechnology (PBYI) versus Repros Therapeutics (RPRX)
www.americanbankingnews.com - September 23 at 6:30 AM |
 | Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference
finance.yahoo.com - September 19 at 6:24 AM |
 | Stocks Under Scanner in the Biotech Space -- Puma Biotech, Regeneron Pharma, Sarepta Therapeutics, and Seattle ... - PR Newswire (press release)
www.prnewswire.com - September 14 at 9:01 AM |
| Before You Buy Puma Biotechnology Inc’s (PBYI), You Should Consider This
finance.yahoo.com - September 14 at 9:01 AM |
| Credit Suisse Group Increases Puma Biotechnology Inc (PBYI) Price Target to $136.00
www.americanbankingnews.com - September 11 at 10:44 AM |
| Puma Biotechnology Inc (PBYI) Now Covered by Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:16 PM |
 | Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast ... - Business Wire (press release)
www.businesswire.com - September 10 at 6:20 AM |
| Puma Biotechnology Inc (PBYI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 9 at 11:46 AM |
| Puma Biotech (PBYI) Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO
www.streetinsider.com - September 9 at 7:13 AM |
| Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress
finance.yahoo.com - September 9 at 7:13 AM |
| Puma Biotechnology Inc (PBYI) SVP Richard Paul Bryce Sells 15,000 Shares
www.americanbankingnews.com - September 8 at 7:32 PM |
| Brokerages Anticipate Puma Biotechnology Inc (PBYI) to Announce -$2.36 EPS
www.americanbankingnews.com - September 8 at 2:28 AM |
| Puma Biotechnology Announces Publication of Abstracts for ESMO 2017
finance.yahoo.com - August 31 at 8:35 AM |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - August 27 at 5:30 AM |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - August 26 at 8:10 AM |
| $7.16 Million in Sales Expected for Puma Biotechnology Inc (PBYI) This Quarter
www.americanbankingnews.com - August 22 at 9:44 AM |
 | Puma Biotech Stock Offers Opportunity To Cash In On Its Maiden Product Launch
seekingalpha.com - August 16 at 6:39 AM |
| Puma Biotechnology Inc (PBYI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 15 at 1:00 PM |
| Puma Biotechnology Becomes Oversold (PBYI)
www.nasdaq.com - August 12 at 6:43 AM |
| Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus - Nasdaq
www.nasdaq.com - August 11 at 7:24 AM |
| Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
finance.yahoo.com - August 11 at 7:24 AM |
| Puma Biotechnology Inc (PBYI) Posts Earnings Results, Misses Estimates By $0.78 EPS
www.americanbankingnews.com - August 11 at 12:40 AM |
| Puma Biotechnology Inc (PBYI) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - August 10 at 7:46 PM |
| Puma Biotechnology Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 6:43 AM |
| Puma Biotech reports 2Q loss
finance.yahoo.com - August 10 at 6:43 AM |
| PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ... - PR Newswire (press release)
www.prnewswire.com - August 6 at 1:14 AM |
| Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?
finance.yahoo.com - August 5 at 6:00 AM |
| PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI
finance.yahoo.com - August 5 at 6:00 AM |
| Puma Biotech (PBYI) Receives Day-180 List of Outstanding Issues from CHMP Related to Neratinib MAA
www.streetinsider.com - August 4 at 6:49 AM |
| What's in Store for Puma (PBYI) this Earnings Season?
www.nasdaq.com - August 4 at 6:49 AM |
| FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps - Nasdaq
www.nasdaq.com - August 3 at 6:48 AM |
| Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human ... - Business Wire (press release)
www.businesswire.com - August 3 at 6:47 AM |
| What's in Store for Puma (PBYI) this Earnings Season?
finance.yahoo.com - August 3 at 6:47 AM |
| Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)
finance.yahoo.com - August 3 at 6:47 AM |
Puma Biotechnology (PBYI) Chart for Saturday, October, 21, 2017
